Antigen-specific impairment of adoptive T-cell therapy against cancer: players, mechanisms, solutions and a hypothesis-Reference-Cited by-同舟云学术

Antigen-specific impairment of adoptive T-cell therapy against cancer: players, mechanisms, solutions and a hypothesis

Published:2016-06-20 Issue:1 Volume:272 Page:169-182
ISSN:0105-2896
Container-title:Immunological Reviews
language:en
Short-container-title:Immunol Rev

Author:

Villadangos Jose A.¹²

Affiliation:

1. Department of Microbiology and Immunology; Doherty Institute of Infection and Immunity; The University of Melbourne; Melbourne Vic. Australia

2. Department of Biochemistry and Molecular Biology; Bio21 Molecular Science and Biotechnology Institute; The University of Melbourne; Melbourne Vic. Australia

Funder

Leukemia and Lymphoma Society

the Cancer Council of Victoria (Australia)

National Health and Medical Research Council

Publisher

Wiley

Subject

Immunology,Immunology and Allergy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/imr.12433/fullpdf

Reference65 articles.

1. Adoptive immunotherapy for cancer: harnessing the T cell response;Restifo;Nat Rev Immunol,2012

2. Gene-engineered T cells for cancer therapy;Kershaw;Nat Rev Cancer,2013

3. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors;Kochenderfer;Nat Rev Clin Oncol,2013

4. Adoptive immunotherapy for cancer or viruses;Maus;Annu Rev Immunol,2014

5. Is cancer gene therapy an empty suit?;Brenner;Lancet Oncol,2013

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cytotoxic T Lymphocytes Control Growth of B16 Tumor Cells in Collagen–Fibrin Gels by Cytolytic and Non-Lytic Mechanisms;Viruses;2023-06-27

2. Mathematical modeling suggests cytotoxic T lymphocytes control growth of B16 tumor cells in collagin-fibrin gels by cytolytic and non-lytic mechanisms;2023-03-29

3. Advances of Tumorigenesis, Diagnosis at Early Stage, and Cellular Immunotherapy in Gastrointestinal Malignancies;Frontiers in Oncology;2021-08-09

4. Beyond Tumor Mutation Burden: Tumor Neoantigen Burden as a Biomarker for Immunotherapy and Other Types of Therapy;Frontiers in Oncology;2021-04-29

5. Recombinant AAV-CEA Tumor Vaccine in Combination with an Immune Adjuvant Breaks Tolerance and Provides Protective Immunity;Molecular Therapy - Oncolytics;2019-03